Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PDCD1LG2 | Q9BQ51 | 3/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18289455 | 0.81 | KCNA5 (0.36) | CTSDKCNA5PDCD1LG2CD274 | |
| SCHEMBL12604536 | 0.80 | CTSD (0.37) | CTSDGAAIRAK4KCNA5TDP1 | |
| SCHEMBL6962558 | 0.80 | CTSD (0.37) | CTSDGAAIRAK4KCNA5TDP1 | |
| SCHEMBL8271490 | 0.80 | CTSD (0.37) | CTSDGAAIRAK4KCNA5TDP1 | |
| SCHEMBL13484370 | 0.78 | — | — | |
| SCHEMBL2731412 | 0.78 | — | — | |
| SCHEMBL13484265 | 0.78 | — | — | |
| SCHEMBL6957136 | 0.78 | CD274 (0.39) | PDCD1LG2CD274 | |
| SCHEMBL24127744 | 0.77 | CTSD (0.36) | CTSDIRAK4PDCD1LG2CD274 | |
| SCHEMBL22259093 | 0.77 | IRAK4 (0.34) | CTSDIRAK4PDCD1LG2CD274KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2019-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336762-B2 | Pyrrolo[1,2-b]pyridazine derivatives | SDHB, CYP4F2, CYP1B1 | CTSD 4078/4885OPRM1 708/4885OPRL1 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.